The use of mesoporous silica in targeted cancer therapy is increasing daily. The combination of a rigid model of nanoparticles like mesoporous silica and biological compounds with an affinity for oncological diseases is the most promising drug-targeting system nowadays. In this study, we used the mesoporous silica SBA-15 combined with aptamer (functionalized for tumor with MUC1). The results obtained were of interest and showed the formation of the silica mesoporous structure. The impregnation methodology of mesoporous silica with the aptamer was also confirmed. Cytotoxicity results demonstrated that the particle associated with the aptamer has no cytotoxicity. We conclude that although further studies are required, the mesoporous silica nanoparticle model loaded with aptamer is very functional and can be used for other applications, especially in nuclear medicine.

1.
Zhun J, et al: Small mesoporous silica nanoparticles as carriers for enhanced photodynamic therapy. Chem Asian J 2011;6:2332–2338.
2.
Morelli C, et al: PEG-templated mesoporous silica nanoparticles exclusively target cancer cells. Nanoscale 2011;3:3198–3207.
3.
Lu J, et al: In vivo tumor suppression efficacy of mesoporous silica nanoparticles-based drug-delivery system: enhanced efficacy by folate modification. Nanomedicine 2012;8:212–220.
4.
Lu J, Liong M, Zink JI, Tamanoi F: Mesoporous silica nanoparticles as a delivery system for hydrophobic anticancer drugs. Small 2007;3:1341–1346.
5.
Ambrogio MW, et al: Mechanized silica nanoparticles: a new frontier in theranostic nanomedicine. Acc Chem Res 2011;44:903–913.
6.
Borbas KE, Ferreira CSM, Perkins A, Bruce JI, Missailidis S: Design and synthesis of mono- and multimeric targeted radiopharmaceuticals based on novel cyclen ligands coupled to anti-MUC1 aptamers for the diagnostic imaging and targeted radiotherapy of cancer. J Bioconjug Chem 2007;18:1205–1212.
7.
Perkins A, Missailidis S: Radiolabelled aptamers for tumour imaging and therapy. Q J Nucl Med Mol Imaging 2007;51:292–296.
8.
Missailidis S, Perkins A: Aptamers as novel radiopharmaceuticals: their applications and future prospects in diagnosis and therapy. Cancer Biother Radiopharm 2007;22:453–468.
9.
Ferreira CSM, Cheung MC, Missailidis S, Bisland S, Gariépy J: Phototoxic aptamers selectively enter and kill epithelial cancer cells. Nucleic Acids Res 2009;37:866–876.
10.
Ferreira CSM, Papamichael K, Guilbault G, Schwarzacher T, Gariepy J, Missailidis S: DNA aptamers against MUC1: design of aptamer-antibody sandwich ELISA for early tumour diagnosis. Anal Bioanal Chem 2008;390:1039–1050.
11.
DaPieve C, Perkins AC, Missailidis S: Anti-MUC1 aptamers: radiolabelling with 99mTc and biodistribution in MCF-7 tumour-bearing mice. Nucl Med Biol 2009;36:703–710.
12.
Leite Diniz C, Da Pieve C, Perkins A, et al: Pharmacokinetic and biodistribution studies of anti-MUC1 PEGylated aptamers with potential in the targeted radiotherapy of breast cancer. EJC Suppl 2010;8:59–60.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.